History
  • No items yet
midpage
399 F.Supp.3d 479
D. Maryland
2019
Read the full case

Background

  • Plaintiffs (public-health organizations and physicians) challenged FDA’s August 2017 Guidance that extended compliance deadlines for products newly "deemed" tobacco products under the Deeming Rule, alleging APA notice-and-comment violations; the Court vacated that Guidance.
  • The Deeming Rule (effective Aug. 8, 2016) brought many e‑cigarette and other tobacco products within FDA’s premarket review requirements; the original compliance deadlines had passed by the time of vacatur.
  • Plaintiffs asked the Court to order short deadlines: require PMTA/SE filings within 120 days and allow products with timely filings to remain on market up to one year while FDA reviews; also requested quarterly reporting and retention of jurisdiction.
  • Defendants (FDA and HHS) argued the Court should remand to FDA and cautioned that an overly short court‑imposed deadline would overwhelm agency resources and risk abrupt market disruption that could drive users back to combusted tobacco.
  • The Court found a public‑health emergency in youth e‑cigarette use but also observed industry delay in seeking approvals; it adopted a compromise deadline: 10 months to file applications and up to one year market stay while FDA reviews, with limited exemption authority and retained jurisdiction.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Court authority to impose filing/approval timetable after vacatur Court may craft equitable remedy and set short deadlines to restore status quo and protect youth health Agency action/remedies should be left to FDA; courts should remand rather than dictate timetables Court has authority in extraordinary circumstances; imposed 10‑month filing deadline and 1‑year marketing stay for timely filings
Whether remand without vacatur or oversight is appropriate Plaintiffs sought immediate remedial timeline and court orders FDA favored remand so it could set timetable and finalize guidance Court rejected remand without vacatur; fashioned its own interim deadlines while allowing FDA discretion in enforcement and exemptions
Public‑health risk of market disruption vs. need for prompt enforcement Short deadlines necessary to curb youth access and compel industry compliance Short deadlines would create administrative burden and risk adults reverting to combustible tobacco if products disappear Court balanced risks and adopted FDA’s suggested accelerated but not minimal timetable (10 months) to reduce abrupt market exit
Necessity of continued court monitoring (reports/retention) Plaintiffs asked for quarterly FDA reports and active monitoring FDA argued its plan and resources suffice; court oversight unnecessary Court declined to require quarterly reports but retained jurisdiction to act further if needed

Key Cases Cited

  • United States v. R.W. Meyer, Inc., 932 F.2d 568 (6th Cir. 1991) (broad equitable discretion to fashion remedies)
  • Howard v. Pierce, 738 F.2d 722 (6th Cir. 1984) (courts may award declaratory and injunctive relief to ensure agency compliance with statutes)
  • Charter Township of Huron v. Richards, 997 F.2d 1168 (6th Cir.) (court may order agency to modify practices to account for past violations)
  • Northwest Envtl. Def. Ctr. v. Gordon, 849 F.2d 1241 (9th Cir. 1988) (injunctive relief may prescribe future regulatory measures)
  • Coalition for Gov’t Procurement v. Fed. Prison Indus., Inc., 365 F.3d 435 (6th Cir. 2004) (courts can tailor remedial relief against agencies)
  • N. Air Cargo v. U.S. Postal Serv., 674 F.3d 852 (D.C. Cir. 2012) (ordinarily identify error and remand; courts sit as appellate tribunals reviewing agency action)
  • PPG Indus., Inc. v. United States, 52 F.3d 363 (D.C. Cir. 1995) (court’s review role typically leads to remand to agency after finding legal error)
  • N.C. Fisheries Ass’n v. Gutierrez, 550 F.3d 16 (D.C. Cir. 2008) (extraordinary circumstances may justify detailed remedial orders)
  • Maine Med. Ctr. v. Burwell, 841 F.3d 10 (1st Cir. 2016) (district court should remand agency error, quoting PPG Indus.)
  • Cobell v. Norton, 240 F.3d 1081 (D.C. Cir. 2001) (contrast where agency completely failed to act)
  • Nat. Res. Def. Council v. EPA, 489 F.3d 1364 (D.C. Cir. 2007) (contrast where agency actively undermined statute)
  • Sierra Club v. U.S. Army Corps of Eng’rs, 909 F.3d 635 (4th Cir. 2018) (remand without vacatur appropriate only in limited circumstances)
  • Allied‑Signal, Inc. v. U.S. Nuclear Reg. Comm’n, 988 F.2d 146 (D.C. Cir. 1993) (standards for remand without vacatur)
  • NAACP v. HUD, 817 F.2d 149 (1st Cir. 1987) (courts may fashion broad remedies to ensure agency compliance)
Read the full case

Case Details

Case Name: American Academy of Pediatrics v. Food and Drug Administration
Court Name: District Court, D. Maryland
Date Published: Jul 12, 2019
Citations: 399 F.Supp.3d 479; 8:18-cv-00883
Docket Number: 8:18-cv-00883
Court Abbreviation: D. Maryland
Log In